CytoCore, Inc. Establishes New Office in Bio-Pharma Hub.

e2 Collector(TM) and Other Reproductive Cancer Screening and Treatment Tools Move Toward Distribution

PRINCETON, N.J. -- Please replace the release with the following corrected version due to multiple revisions.

The corrected release reads:

CYTOCORE, INC. ESTABLISHES NEW OFFICE IN BIO-PHARMA HUB

e2 Collector(TM) and Other Reproductive Cancer Screening and Treatment Tools Move Toward Distribution

CytoCore, Inc. (OTCBB:CYCR), the late-stage bio-scientific research and medical device company for early reproductive cancer treatment, today announced the opening of its new office in this well-known hub for leading-edge solutions to women's health issues.

"As our suite of early screening, diagnostic and treatment tools moves from the research to production stage, CytoCore wants to be poised to tap into the extensive concentration of capabilities in New Jersey's thriving bio-pharmaceutical business community," said Dr. Augusto Ocana, the Company's chief executive officer, who will be based in the new Princeton, N.J., office. "We're positioning ourselves for an optimal transition into the distribution phase for our endometrial, uterine and cervical cancer products."

Currently engaged in clinical trials for an upgrade to the FDA-cleared e2 Collector sampling device, CytoCore expects upon FDA clearance to be in production by early summer. The new balloon sampling method -- the first significant upgrade to the Pap test in 50 years -- is designed to enhance the thoroughness and consistency of cell collections for the Pap smear performed annually on some 180 million women worldwide. Feasibility studies are underway to evaluate the use of cells collected by the e2 Collector for HPV testing.

"We expect to be ready for volume production by mid-summer, producing up to 800,000 units a month on one shift," Dr. Ocana said. "Not only will we be offering a more cost-effective sample collection method, we're also improving the patient's comfort through our new, non-invasive collection procedure and the physician's confidence in the quality of that sample. We believe that our niche strategy will allow us to drive our products into the markets worldwide."

CytoCore's new office is located at:

212 Carnegie Center, Suite 206

Princeton, N.J. 08540

Telephone: [phone]

Facsimile: 609.520.8731

For further information about the e2 Collector and CytoCore's full suite of products for the early screening, diagnoses and treatment of reproductive cancers, visit www.CytoCoreInc.com.

About CytoCore Inc.

CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com.

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.